Poblano-Verástegui Ofelia, Bautista-Morales Arturo Cuauhtémoc, Acosta-Ruíz Omar, Gómez-Cortez Patricia María, Saturno-Hernández Pedro Jesús
Centro de Investigación en Evaluación y Encuestas, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.
Consorcio Mexicano de Hospitales Privados. Ciudad de México, México.
Salud Publica Mex. 2020 Nov-Dec;62(6):859-867. doi: 10.21149/11919.
To analyze the prevalence of polypharmacy, as well as the factors that identify the groups with higher risk, in population study in Mexico.
Descriptive analysis of the Encuesta Nacional de Salud y Nutrición 2018-19 (Ensanut 2018-19), Utilization of services (medicine section) and Household questionnaires, to obtain prevalence of polypharmacy (simultaneous consumption ≥5 medicines). A logistic regression model was used to estimate the association of polypharmacy with sociodemographic and health care factors.
Prevalence of polypharmacy: 18 years, 15.5%, and 65 years, 26.5%. Higher prevalence in: nephropathies (61.5%), heart disease (42.2%), chronic ob-structive pulmonary disease (38.5%), diabetes (29.3%) and hypertension (26.4%). Increased possibility in adults 65 years (OR:1.95), low schooling (OR:1.54), social security (OR:1.64), serviced in public services (OR:1.7) and chronic illness (OR:1.84).
Polypharmacy is associated with chronic disease and some sociodemographic factors. Large area of opportunity to improve quality of care, particularly pharmacological prescription to identified population with higher risk.
